Table 4.
Subgroup Analysis in SSc
| Plasma Level Median (IQR) | ||||
|---|---|---|---|---|
|
| ||||
| Disease Characteristic and number of subjects | DPP4 (U/L) | P | FAP (pmol AMC/min/mL) | P |
| Antibody status | 0.11 | 0.97 | ||
| 7 Anti-centromere positive | 24.5 (13.5) | 1218.8 (825.3) | ||
| 15 Anti-Scl70 positive | 18.6 (15.9) | 1192.4 (713.7) | ||
| Cutaneous involvement | 0.06 | 0.35 | ||
| 19 Limited | 20.0 (6.7) | 1186.4 (648.4) | ||
| 18 Diffuse | 14.9 (13.7) | 1192.4 (917.3) | ||
| Joint involvement | 0.06 | 0.53 | ||
| 14 Present | 16.1 (7.6) | 1047.4 (1074.6) | ||
| 23 Absent | 20.8 (9.7) | 1218.8 (600.5) | ||
| Digital ulcers | 0.26 | 0.41 | ||
| 18 Present | 18.6 (8.7) | 1079.1 (887.7) | ||
| 19 Absent | 20.6 (11.3) | 1269.9 (645.7) | ||
| Pulmonary fibrosis | 0.36 | 0.78 | ||
| 20 Present | 18.6 (9.8) | 1189.4 (800.9) | ||
| 17 Absent | 20.0 (9.6) | 1044.1 (741.9) | ||
| Pulmonary hypertension | 0.50 | 0.23 | ||
| 11 Present | 19.3 (12.8) | 1114.0 (602.7) | ||
| 26 Absent | 18.6 (10.0) | 1189.4 (780.9) | ||
| Renal involvement | 0.38 | 0.35 | ||
| 4 Present | 16.4 (16.0) | 1445.8 (1255.5) | ||
| 33 Absent | 19.3 (7.9) | 1150.3 (738.2) | ||
| Muscle disease | 0.03 | 0.24 | ||
| 9 Present | 13.3 (9.2) | 1728.9 (1021.5) | ||
| 28 Absent | 20.3 (10.2) | 1132.2 (591.4) | ||
|
| ||||
| Treatment | ||||
|
| ||||
| Prednisone | 0.02 | 0.09 | ||
| 10 Yes | 13.2 (7.9) | 819.9 (1093.0) | ||
| 27 No | 20.6 (10.5) | 1218.8 (594.5) | ||
| Methotrexate | 0.42 | 0.11 | ||
| 5 Yes | 17.0 (10.8) | 1761.9 (1473.3) | ||
| 32 No | 19.7 (9.0) | 1168.4 (746.8) | ||
| Mycophenolate | 0.35 | 0.48 | ||
| 5 Yes | 21.6 (16.3) | 917.2 (834.7) | ||
| 32 No | 18.5 (7.8) | 1192.4 (658.4) | ||
| Cyclophosphamide | 0.25 | 0.33 | ||
| 6 Yes | 14.8 (11.7) | 1097.2 (675.1) | ||
| 30 No | 19.7 (9.5) | 1244.4 (725.0) | ||